TICKERNERD
Menu
STROSTROHealthcare · Biotechnology

STRO Stock Forecast: Sutro Biopharma, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$9.14
−1.61% on the day

The 14 Wall Street analysts covering Sutro Biopharma, Inc. hold a median 12-month price target of $50 — +447.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$154.0M
Ticker Nerd rank
75/ 100
Median analyst target
$50
Analysts covering
14
Revenue$9.8M−84.6% y/y
Operating income−$29.7M
Net income−$38.5M
Free cash flow−$38.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.2%
1M
−43.2%
YTD
−21.0%
1Y
−13.0%
From 52W high
−77.7%
From 52W low
+25.2%
$7
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STRO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sutro Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
75/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Accruals
84
Revisions
75
Size
70
Value
66
Momentum
58
Quality
49
Volatility
43
Issuance
6

Growth (87): Sales and profits are climbing, and climbing faster than before.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

STRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STRO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26STROHigh $61Median $50Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13 Buy0 Hold1 Sell
Low $10Median $50High $61

The green dot is the last close — the median target sits +447.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Oct 2026WedbushReiteratesOutperform$60
13 Aug 2026CitizensMaintainsMarket Outperform$41 → $34
13 Aug 2026CitizensMaintainsMarket Outperform—
13 Aug 2026WedbushReiteratesOutperform$60
13 Aug 2026WedbushReiteratesOutperform—
11 June 2026Truist SecuritiesAssumesBuy$50
28 May 2026BarclaysInitiatesOverweight—
15 May 2026HC Wainwright & Co.MaintainsBuy—
15 May 2026Leerink PartnersMaintainsOutperform—
15 May 2026WedbushUpgradeOutperform—
30 Apr 2026MizuhoInitiatesOutperform—
23 Apr 2026CitizensMaintainsMarket Outperform—
17 Apr 2026CitizensMaintainsMarket Outperform—
7 Apr 2026Leerink PartnersInitiatesOutperform—
25 Mar 2026Deutsche BankMaintainsBuy—
24 Mar 2026HC Wainwright & Co.UpgradeBuy—
24 Mar 2026Wells FargoUpgradeOverweight—
20 Jan 2026CitizensUpgradeMarket Outperform—
22 Dec 2025HC Wainwright & Co.MaintainsNeutral—
12 Aug 2025Wells FargoMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

STRO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

STRO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Sutro Biopharma, Inc. returned −13.0% against +13.1% for the S&P 500, dividends included.

STRO vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Jan 26Apr 26Jul 26Oct 26STROS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Sutro Biopharma, Inc. (STRO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 80% of US stocks

Price / sales
3.4×

Cheaper than 37% of US stocks

Price / book
−1.5×

Cheaper than 95% of US stocks

EV / EBITDA
−0.0×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−84.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−84.6%

Higher than 4% of US stocks

Gross margin
—
Operating margin
−301.7%

Higher than 9% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
144.3%

Higher than 97% of US stocks

Return on assets
−36.1%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sutro Biopharma, Inc. (STRO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sutro Biopharma, Inc. has a market value of $154.0M and an enterprise value of $476K.

  • Revenue in the twelve months to 30 June 2026: $45.7M. The latest quarter shrank 84.6% year on year.

  • Net income over the same four quarters: −$180.6M, a −395.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$145.6M.

  • Shares outstanding: 16.6M.

  • Trailing P/E: −0.4×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Sutro Biopharma, Inc. employs 128 people — $357K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

STRO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
STROSutro Biopharma, Inc.$154.0M75
MENSJyong Biotech Ltd.$152.2M3
CUECue Biopharma, Inc.$153.7M30
MGNXMacroGenics, Inc.$157.0M62
CNTNCanton Strategic Holdings, Inc.$157.3M11
TARAProtara Therapeutics, Inc.$147.1M34
PDSBPDS Biotechnology Corp.$159.6M78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sutro Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STRO news & analysis

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

GlobeNewsWire · 21 Oct 2026positive

Sutro Biopharma announced that the first patient has been dosed in its Phase 1 trial of STRO-006, an ITGB6-targeting antibody-drug conjugate, in patients with advanced solid tumors. The company said it expects initial clinical data in the second half of 2027.

Why it matters — The trial's start marks a new clinical-stage program for Sutro, with initial data expected in the second half of 2027.

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

GlobeNewsWire · 29 Sept 2026neutral

Sutro Biopharma announced the appointment of Lucas Donigian as Senior Vice President of Business Development, effective September 28, 2026. Donigian will lead business development activities for the clinical-stage oncology company focused on antibody drug conjugates.

Why it matters — The appointment brings new leadership to Sutro's business development function, which STRO watchers may see as meaningful for the company's future partnerships and collaborations.

Why is Sutro Biopharma Stock Falling On Wednesday?

Benzinga · 12 Aug 2026negative

Sutro Biopharma shares are trading lower on Wednesday, according to the report, as the company faces challenges following its recent update on the STRO-004 Phase 1 study.

Why it matters — A STRO watcher would care because the company is contending with challenges stemming from its STRO-004 Phase 1 study update, which is weighing on the stock.

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

GlobeNewsWire · 12 Aug 2026positive

Sutro Biopharma reported its second quarter 2026 financial results and provided an early update on its STRO-004 Phase 1 study, citing encouraging clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability and pharmacokinetics. The company reported $164.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028, and noted that STRO-006 is on track to enter the clinic in Q3 2026 while a second dual-payload program under the Astellas collaboration is expected to enter the clinic in the second half of 2026.

Why it matters — The early positive clinical data for STRO-004, on-track progress of STRO-006 and the Astellas collaboration program, and a cash runway through at least Q2 2028 give STRO watchers insight into the company's pipeline momentum and financial stability.

FAQ

Frequently asked questions about STRO stock

What is the STRO stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Sutro Biopharma, Inc. have a median 12-month price target of $50, with estimates ranging from $10 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STRO stock a buy right now?

Of the 14 analysts covering Sutro Biopharma, Inc., 13 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sutro Biopharma, Inc. 75 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STRO?

As at 28 Oct 2026, Sutro Biopharma, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will STRO stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +447.0% from the last close, and Ticker Nerd's factor model ranks Sutro Biopharma, Inc. 75 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STRO stock forecast for 2030?

No analyst covering Sutro Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $61 over the next 12 months.

How has STRO stock performed over the past year?

Sutro Biopharma, Inc. returned -13.0% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sutro Biopharma, Inc. do?

Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics.

What is the latest news on STRO?

The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors". Sutro Biopharma announced that the first patient has been dosed in its Phase 1 trial of STRO-006, an ITGB6-targeting antibody-drug conjugate, in patients with advanced solid tumors. The company said it expects initial clinical data in the second half of 2027.

Company

About Sutro Biopharma, Inc.

Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. The company designs and advances antibody-drug conjugates, including site-specific, single-payload, dual-payload, and immunostimulatory formats, using its proprietary XpressCF and XpressCF+ platforms. These technologies support the discovery, development, and manufacture of biologic drug candidates intended for oncology and other immune-related diseases. Sutro Biopharma’s work centers on creating precisely engineered therapies for solid tumors and hematologic cancers, while also supporting collaborative research and development efforts with pharmaceutical partners. Headquartered in South San Francisco, California, Sutro Biopharma plays a specialized role in the biopharmaceutical market by combining protein engineering, drug conjugation, and therapeutic development within a single platform-driven approach.

CEO Ms. Jane Chung R.Ph. · 128 employees · United States · https://www.sutrobio.com